Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer
Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the biologically active dose of entinostat, when
given in combination with avelumab, that is safe and warrants further investigation.
Additionally, this study will evaluate the effectiveness of entinostat in combination with
avelumab at the determined dose in terms of progression free survival compared to avelumab
plus placebo in patients with refractory or recurrent epithelial ovarian cancer.